PMID- 26600634
OWN - NLM
STAT- MEDLINE
DCOM- 20160617
LR  - 20181113
IS  - 1998-3751 (Electronic)
IS  - 0253-7613 (Print)
IS  - 0253-7613 (Linking)
VI  - 47
IP  - 5
DP  - 2015 Sep-Oct
TI  - TNFerade, an innovative cancer immunotherapeutic.
PG  - 479-83
LID - 10.4103/0253-7613.165190 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a chemokine with effective tumoricidal 
      properties. However, severe systemic toxicity limits its use of as anticancer 
      agent. TNFerade is a novel replication deficient adenovector based gene therapy, 
      which enables the radiation inducible translation of human TNF-alpha gene 
      specifically in cancer cells. When injected intratumorally, it has least systemic 
      distribution. Consequently, it lacks TNF-alpha related systemic toxicity. Evidence 
      suggests that it has superior tumoricidal activity and tolerability with minimum 
      adverse effects. It has demonstrated its beneficial role in the treatment of a 
      variety of cancers in terms of improving the disease free and overall survival, 
      delaying tumor progression, and inducing tumor regression when used with 
      concurrent radiotherapy or chemotherapy.
FAU - Kali, Arunava
AU  - Kali A
AD  - Department of Microbiology, Mahatma Gandhi Medical College and Research 
      Institute, Puducherry, India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Pharmacol
JT  - Indian journal of pharmacology
JID - 7902477
RN  - 0 (TNFeraseBiologic)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Animals
MH  - DNA/administration & dosage
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Genetic Therapy/*methods
MH  - Humans
MH  - Immunotherapy/methods
MH  - Neoplasms/genetics/immunology/*therapy
MH  - Survival Rate
MH  - Tumor Necrosis Factor-alpha/*genetics
PMC - PMC4621666
OTO - NOTNLM
OT  - Cancer immunotherapy
OT  - TNFerade
OT  - gene therapy
OT  - tumor necrosis factor-alpha
EDAT- 2015/11/26 06:00
MHDA- 2016/06/18 06:00
PMCR- 2015/09/01
CRDT- 2015/11/25 06:00
PHST- 2015/11/25 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/06/18 06:00 [medline]
PHST- 2015/09/01 00:00 [pmc-release]
AID - IJPharm-47-479 [pii]
AID - 10.4103/0253-7613.165190 [doi]
PST - ppublish
SO  - Indian J Pharmacol. 2015 Sep-Oct;47(5):479-83. doi: 10.4103/0253-7613.165190.